A phase 2 trial of gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, now recruiting.
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma is a phase 2 interventional study registered as NCT07570849 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 35 participants, started 2026-03-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor. Conditions listed: Intrahepatic Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: "3. Patients with histologically or pathologically confirmed unresectable or metastatic intrahepatic cholangiocarcinoma (ICC). Patients with extrahepatic cholangiocarcinoma (EHCC) or gallbladder cancer (GBC) are excluded.". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/